NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Quick Stats
Apr 01, 202649.0
AI Score
HOLD0.53
Volume Ratio
Apr 23, 2026
Next Earnings
11
+ve Days (30d)
19
-ve Days (30d)
NVCR Stock Summary
Last updated Apr 01, 2026
NVCR is currently trading at $10.84, positioned below its 200-day moving average of $13.11, suggesting bearish momentum. The stock has a 52-week range of $9.82 to $20.06.
Technical Analysis: The 50-day moving average stands at $12.12, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 39.912, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.168, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates NVCR at 49.0/100 with a HOLD recommendation.
NVCR (NovoCure Limited Ordinary Shares) Indicators
Last updated Apr 01, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 39.912 |
| CMF (20) | -0.168 |
| ROC (10) | -10.116 |
| ADX (14) | 13.973 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.448 |
| AROONOSC (14) | -71.429 |
| WILLAMS %R (14) | -77.176 |
| MFI (14) | 61.003 |
NVCR Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
NVCR Price vs Max Options Open Interest
NVCR Max Change In Options Open Interest
NVCR Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVCR Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVCR Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVCR Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NovoCure Limited Ordinary Shares is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
NVCR Moving Averages Analysis
NVCR (NovoCure Limited Ordinary Shares) Simple Moving Averages
Moving Averages are last updated Apr 01, 2026
| Days | MA |
|---|---|
| 10 | 11.36 |
| 20 | 12.0 |
| 30 | 12.27 |
| 50 | 12.12 |
| 100 | 12.4 |
| 200 | 13.11 |
NVCR Fundamental Analysis
| P/E (Forward) | 909.0909 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.2 billion |
| Earnings/Share ($) | -1.22 |
| Net Proft Margin (%) | -0.2079 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -1.5357 |
| EPS Estimate Next Year ($) | -1.1657 |
| WallStreet Target Price ($) | 26.0714 |
| Most Recent Quarter |
Novocure ($NVCR) stock sees a double bottom at $3.11, leading to a perfect buy opportunity with no dilution and over $1 billion in cash. The company's pancreatic cancer therapy is expected to boost sales over $1 billion, with the FDA approval of its Optune Pax device for locally advanced pancreatic cancer. H.C. Wainwright raises price target to $47 from $39 after FDA approval. Target price set at $16.00 to $25.00. Earnings call scheduled for Feb 26.
Updated 2026-02-12 17:00:02